Novo Nordisk veteran takes up CMO position at Danish-Swedish biotech company

Anders Dyhr Toft, who has worked for Novo Nordisk for many years, will step into the role of CMO at SynAct Pharma on Aug. 1.

Synact Pharma CEO Jeppe Øvlesen | Photo: Synact Pharma / PR

On Wednesday, SynAct Pharma appointed Anders Dyhr Toft as its Chief Medical Officer (CMO). This will come into effect on Aug. 1, according to a company press release.

At SynAct Pharma, Anders Dyhr Toft will collaborate with Synact's Chief Scientific Officer (CSO) Thomas Jonassen. Together, they will head up clinical development and medical affairs at the Swedish-listed biotech company, which is currently running trials involving its main candidate AP1189, which SynAct is testing within rheumatoid arthritis, nephrotic syndrome, and most recently, an adjunctive treatment for patients with covid-19.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs